Orchid Pharma Limited (BOM:524372)
707.55
+4.25 (0.60%)
At close: Jun 27, 2025
Orchid Pharma Revenue
In the fiscal year ending March 31, 2025, Orchid Pharma had annual revenue of 9.22B INR with 12.52% growth. Orchid Pharma had revenue of 2.37B in the quarter ending March 31, 2025, with 9.39% growth.
Revenue
9.22B
Revenue Growth
+12.52%
P/S Ratio
3.98
Revenue / Employee
10.58M
Employees
871
Market Cap
36.73B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 9.22B | 1.03B | 12.52% |
Mar 31, 2024 | 8.19B | 1.53B | 23.05% |
Mar 31, 2023 | 6.66B | 1.06B | 19.00% |
Mar 31, 2022 | 5.60B | 1.09B | 24.33% |
Mar 31, 2021 | 4.50B | -337.41M | -6.97% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,646.93B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,729.85B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,429.39B |
Infosys | 1,647.16B |
Life Insurance Corporation of India | 8,901.58B |
Orchid Pharma News
- 5 weeks ago - Orchid Pharma shares drop nearly 5% as Q4 net profit falls 32.4% YoY to Rs 22.3 crore - Business Upturn
- 4 months ago - Orchid Pharma shares surge 4.4% after successful USFDA inspection at Alathur API facility - Business Upturn
- 4 months ago - Orchid Pharma successfully completes USFDA inspection at Alathur API facility, secures EU GMP certification renewal - Business Upturn
- 5 months ago - Orchid Pharma shares drop over 14% as net profit falls 25.63% YoY to ₹22.45 crore in Q3 - Business Upturn
- 8 months ago - Orchid Pharma shares jump nearly 4% following strong Q2 FY25 results - Business Upturn
- 8 months ago - Orchid Pharma Q2 FY25 Results: Revenue jumps 12% to ₹222.7 crore, PAT up 26% YoY - Business Upturn